US$ 23.18
cagrilintide vs tirzepatide A new drug combo of semaglutide (GLP-1 receptor agonist) with (amylin analogue) failed to do as well as (GLP-1/GIP receptor agonist). The future of these medicines is hitting different receptors Unlocking the Power of Cagrilintide:
Description
It's a bodyweight, so it's not much weight

Participants in the liraglutide group demonstrated a similar pattern, with mean weight loss decreasing from 8.5% at week 26 to 7.2% at week 32, indicating partial weight gain after discontinuation [1]

Johnson, K

Colombo, P., Zordan, F

Inflammation 40 , 861870 (2017)